Co-Diagnostics Inc. (NASDAQ: CODX) stock gained by 1.26% at last close while the CODX stock price rises by 11.58% in the after-hours trading. Co-Diagnostics is a molecular diagnostics business based in Utah that develops, produces, and distributes a novel, cutting-edge diagnostics technology.
>> 7 Top Picks for the Post-Pandemic Economy <<
CODX stock, Financial Highlights
Following are the financial results released by Co-Diagnostics for its second quarter 2021.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
- Revenue generated for Q2 2021 was $27.4 million, up 13.8 percent over the prior year quarter, was largely attributable to sales of the Logix Smart COVID-19 Test.
- Due to lower manufacturing costs and a better product mix, gross profit grew 37.6% to $24.9 million, accounting for 90.8 percent of consolidated sales, compared to the prior-year quarter.
- Higher sales and marketing expenditures as a consequence of increased third-party sales commissions, as well as greater research and development costs linked to the Eikon point of care technology platform, resulted in operating income of $11.8 million, a 19.8% reduction from the prior year quarter.
- Net income was $9.8 million, relative to $15.0 million in the first quarter of the preceding year, or $0.33 per fully diluted share, vs $0.51 per fully diluted share in the second quarter of 2020.
- As of June 30, 2021, cash, cash equivalents, and marketable securities totaled $72.4 million, up $12.3 million from March 31, 2021.
- For the year-to-date period ended June 30, 2021, operating cash flows totaled $24.7 million, relative to $0.3 million in cash utilized in operations in the prior year period.
Read More
Q3 2021 Insight
For the third quarter of 2021, Co-Diagnostics has provided the following assistance:
- Revenue is expected to be between $23.0 million to $25.0 million.
- Expenditure for their Eikon point-of-care technology platform have grown.
- With shares outstanding estimated to be around 30 million and a corporate effective tax rate of around 19.0 percent, diluted earnings per share is anticipated to be in the $0.19 to $0.22 range.